News for Geron Corporation (GERN)

PR NewswireNEW YORK, March 3, 2025 NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Geron Corporatio

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Geron Corporation (”œGeron” or th

Feb 26, 2025 / 01:00PM GMTOperator Hello, and welcome to the Geron first-quarter and full year 2024 earnings call. (Operator instructions). I would now like to

PR NewswireNEW YORK, Feb. 26, 2025 NEW YORK, Feb. 26, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Geron Corporati

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Wednesday. The Dow traded down 0.32% to 43,482.16 ...

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining around 150 points on Wednesday. The Dow traded down 0.06% to 43,594....

Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new patients starts flat. Read more here.

Geron Corporation (NASDAQ:GERN) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ETCompany ParticipantsAron Feingold - VP of IR and Corporate...

Shares of Geron (GERN) plunged 30% early Wednesday after the company released its Q4 earnings report. Read more here.

The following slide deck was published by Geron Corporation in conjunction with their 2024 Q4 earnings call.

We recently published a list of 10 Best Nasdaq Stocks Under $5 to Buy. In this article, we are going to take a look at where Geron Corp.

**media[537513]**

We argue against selling Geron at current prices, citing strong market potential of imetelstat and Royalty Pharma deal valuation. Read more on GERN stock here.

Despite some market exclusivity concerns, GERN still has many years of sales ahead, unencumbered by generic competition. Explore more details here.

Geron Corp (GERN), a commercial-stage biopharmaceutical company, announced on January 17, 2025, that it has granted equity awards totaling 312,000 shares of its

Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 312,0

We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this article, we are going to take a look at where Geron Corporation (NASDAQ:GERN) stands against other stocks ...

FDA's approval of GERN's Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year.

Ten companies kicked off this week's trading mirroring a decline on Dow Jones with a series of catalysts dampening investor sentiment.